ADA assay development: a podcast interview with Lynn Kamen

Antibodies | ADCs Interviews

In this In the Zone podcast, we explore with Lynn Kamen, Scientific Officer at BioAgilytix (NC, USA), what ADAs are, their importance in drug development and the different advantages and disadvantages of sample pretreatment in ADA assay development.

Questions

1. What are ADAs and why are they so important in drug development?
2. How do you measure ADAs in patients?
3. How can circulating drug interfere in ADA measurement?
4. What methods can be used to decrease drug interference in assays?
5. What are the pros and cons of the different forms of sample pretreatment?

In association with: